Search

Your search keyword '"Sia, Hanlon"' showing total 16 results
Start Over Author "Sia, Hanlon"
16 results on '"Sia, Hanlon"'

1. Ibrutinib plus rituximab and mini-CHOP in older patients with newly diagnosed DLBCL: a phase 2 ALLG study

Author

Lenton, Douglas, Taper, John, Presgrave, Peter, Butler, Jason, Mollee, Peter, Kannourakis, George, Steer, Christopher, Verner, Emma, Johnston, Amanda, Pati, Nalini, Hawkes, Eliza A., Lee, Hui-Peng, Cochrane, Tara, Cheah, Chan Yoon, Filshie, Robin, Purtill, Duncan, Sia, Hanlon, Enjeti, Anoop K., Brown, Christina, Murphy, Nicholas, Curnow, Jennifer, Lee, Kenneth, Gandhi, Maher K., Walia, Mannu, Butcher, Belinda E., and Trotman, Judith

Published
2024
Full Text
View/download PDF

3. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

Author

Moreau, Philippe, Dimopoulos, Meletios-Athanasios, Mikhael, Joseph, Yong, Kwee, Capra, Marcelo, Facon, Thierry, Hajek, Roman, Spicka, Ivan, Baker, Ross, Kihyun, Kim, Martinez, Gracia, Chang-Ki, Min, Pour, Ludek, Leleu, Xavier, Oriol, Albert, Youngil, Koh, Suzuki, Kenshi, Martin, Tom, Quach, Hang, Lim, Andrew, Crowther, Helen, Sia, Hanlon, Hulin, Cyrille, Mohty, Mohamad, Mikala, Gabor, Nagy, Zsolt, Reinoso Segura, Marta, Rosinol, Laura, Yagci, Munci, Turgut, Mehmet, Garg, Mamta, Parmar, Gurdeep, Augustson, Brad, Castro, Nelson, Crusoe, Edvan, Pika, Tomas, Delimpasi, Sosana, Ishizawa, Kenichi, George, Anup, Konstantinova, Tatiana, De La Rubia, Javier, Sung-Hyun, Kim, Maiolino, Angelo, Reiman, Anthony, LeBlanc, Richard, Ito, Shigeki, Tanaka, Junji, Luchinin, Alexander, Kryuchkova, Irina, Martinez, Joaquin, Shustik, Jesse, Karlin, Lionel, Symeonidis, Anargyros, Egyed, Miklos, Petrini, Mario, Cavo, Michele, Uchiyama, Michihiro, Blacklock, Hilary, Arat, Mutlu, Griffin, James, Hunter, Hannah, Buck, Tonda, Anagnostopoulos, Achilles, Konstantopoulos, Konstantinos, Masszi, Tamas, Bringhen, Sara, Gamberi, Barbara, Kawano, Yawara, Jin Seok, Kim, Ozdogu, Hakan, Ozkalemkas, Fahir, Špička, Ivan, Kim, Kihyun, Min, Chang-Ki, Koh, Youngil, Risse, Marie-Laure, Asset, Gaelle, Macé, Sandrine, and Martin, Thomas

Published
2021
Full Text
View/download PDF

4. Ibrutinib plus rituximab and mini-CHOP in older patients with newly diagnosed DLBCL: a phase 2 ALLG study

Author

Verner, Emma, Johnston, Amanda, Pati, Nalini, Hawkes, Eliza A., Lee, Hui-Peng, Cochrane, Tara, Cheah, Chan Yoon, Filshie, Robin, Purtill, Duncan, Sia, Hanlon, Enjeti, Anoop K., Brown, Christina, Murphy, Nicholas, Curnow, Jennifer, Lee, Kenneth, Gandhi, Maher K., Walia, Mannu, Butcher, Belinda E., Trotman, Judith, Lenton, Douglas, Taper, John, Presgrave, Peter, Butler, Jason, Mollee, Peter, Kannourakis, George, and Steer, Christopher

Abstract

•Ibrutinib–R-mini-CHOP was a deliverable combination in patients with DLBCL aged ≥75 years.•Ibrutinib–R-mini-CHOP improves PFS compared with historical rates reported for R-mini-CHOP, but this study did not demonstrate a superior OS.

Published
2024
Full Text
View/download PDF

5. P1127: FINAL ANALYSIS OF AUSTRALASIAN LEUKAEMIA & LYMPHOMA GROUP NHL29: A PHASE II STUDY OF IBRUTINIB, RITUXIMAB AND MINI-CHOP IN VERY ELDERLY PATIENTS WITH NEWLY DIAGNOSED DLBCL

Author

Verner, Emma, primary, Johnston, Amanda, additional, Pati, Nalini, additional, Hawkes, Eliza, additional, Peng Lee, Hui, additional, Cochrane, Tara, additional, Yoon Cheah, Chan, additional, Filshie, Robin, additional, Purtill, Duncan, additional, Sia, Hanlon, additional, Enjeti, Anoop K, additional, Brown, Christina, additional, Murphy, Nicholas, additional, Curnow, Jennifer, additional, Lee, Kenneth, additional, Gandhi, Maher, additional, Butcher, Belinda, additional, and Trotman, Judith, additional

Published
2023
Full Text
View/download PDF

7. A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple Myeloma

Author

Sia, Hanlon, primary, Tan, Peter T., additional, Richter, Joshua, additional, Ho, Phoebe Joy, additional, Cochrane, Tara, additional, Quach, Hang, additional, Dhakal, Binod, additional, Proscurshim, Igor, additional, Jiang, Tony, additional, Mancino, Emaryn, additional, Salhi, Yacine, additional, Stefano, Sammicheli, additional, Gudi, Girish, additional, Garton, Andrew, additional, Feldman, Eric J., additional, and Spencer, Andrew, additional

Published
2022
Full Text
View/download PDF

9. Efficacy of Ibrutinib, Rituximab and Mini-CHOP in Very Elderly Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma: Primary Analysis of the Australasian Leukaemia & Lymphoma Group NHL29 Study

Author

Verner, Emma, primary, Johnston, Amanda, additional, Pati, Nalini, additional, Hawkes, Eliza, additional, Lee, Hui-Peng, additional, Cochrane, Tara, additional, Cheah, Chan-Yoon, additional, Filshie, Robin J, additional, Purtill, Duncan, additional, Sia, Hanlon, additional, Enjeti, Anoop Kumar, additional, Brown, Christina, additional, Murphy, Nicholas E., additional, Curnow, Jennifer, additional, Lee, Kenneth, additional, Walia, Mannu, additional, Butcher, Belinda, additional, and Trotman, Judith, additional

Published
2021
Full Text
View/download PDF

10. Initial Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

Author

Kazandjian, Dickran, Quach, Hang, Sia, Hanlon, Ho, Phoebe Joy, Spencer, Andrew, Schroeder, Mark A., Dhakal, Binod, Cochrane, Tara, Zonder, Jeffrey A., Yi, Nancy, Duchesne, Dominique, Shah, Tejas, Garton, Andrew, Menon, Vinu, Gn, Sunitha, Sammicheli, Stefano, Zhukovsky, Eugene, Konto, Cyril, Pacaud, Lida, and Tan, Peter

Published
2023
Full Text
View/download PDF

13. Depth of Response and Response Kinetics of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Ikema Interim Analysis

Author

Martin, Thomas, primary, Mikhael, Joseph, additional, Hajek, Roman, additional, Kim, Kihyun, additional, Suzuki, Kenshi, additional, Hulin, Cyrille, additional, Garg, Mamta, additional, Quach, Hang, additional, Sia, Hanlon, additional, George, Anup, additional, Konstantinova, Tatiana, additional, Risse, Marie-Laure, additional, Asset, Gaelle, additional, Macé, Sandrine, additional, van de Velde, Helgi, additional, and Moreau, Philippe, additional

Published
2020
Full Text
View/download PDF

14. Trimethoprim‐sulfamethoxazole as Pneumocystis jiroveci pneumonia prevention in patients undergoing methotrexate therapy for hematological malignancies: A review of the literature.

Author

King, Liam D., Sia, Hanlon, and Anoopkumar‐Dukie, Shailendra

Subjects
PNEUMOCYSTIS jiroveci, PNEUMOCYSTIS pneumonia, CO-trimoxazole, METHOTREXATE, ANTI-infective agents, ANTIBIOTIC prophylaxis
Abstract

Methotrexate is a cytotoxic agent that is commonly used to treat autoimmune diseases, and both solid and hematological malignancies. Drug interactions are of particular concern during methotrexate therapy, as they have the potential to alter the pharmacokinetics of methotrexate and lead to significant toxicity. One agent that has the potential to interact with methotrexate is the antimicrobial agent trimethoprim with sulfamethoxazole. Consideration of this interaction is of importance in patients that are undergoing high‐dose methotrexate therapy for hematological malignancies as trimethoprim/sulfamethoxazole is the preferred agent for Pneumocystis jiroveci pneumonia prophylaxis. Current Australian guidelines recommend avoiding concurrent administration of high‐dose methotrexate and trimethoprim/sulfamethoxazole, yet evidence to support this recommendation is unclear. This review investigates the current available evidence that focuses on the interaction between high‐dose methotrexate and trimethoprim/sulfamethoxazole and aims provide guidance for the use of this combination in clinical practice. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

15. Evaluation of a bone morphogenetic protein 6 variant as a cause of iron loading

Author

McDonald, Cameron, Rishi, Gautam, Secondes, Eriza, Ostini, Lesa, Wallace, Daniel, Crawford, Darrell, Sia, Hanlon, Clark, Paul, Subramaniam, V. Nathan, McDonald, Cameron, Rishi, Gautam, Secondes, Eriza, Ostini, Lesa, Wallace, Daniel, Crawford, Darrell, Sia, Hanlon, Clark, Paul, and Subramaniam, V. Nathan

Abstract

Background Atypical iron overload without variation in the five clinically associated hereditary hemochromatosis genes is now recognized; however, their etiology remains unknown. Since the identification of iron overload in the bone morphogenetic protein 6 (Bmp6) knockout mouse, the search has been on for clinically pathogenic variants in the Bmp6 gene. A recent report proposes that variants in the pro-peptide region of Bmp6 are the underlying cause of several cases of iron overload. We performed targeted next-generation sequencing on three cases of atypical iron overload with Asian ethnicity and identified a p.Q118dup (aka p.E112indelEQ, p.Q115dup, p.Q118_L119insQ) variant in BMP6. The purpose of this study was to characterize the molecular function of the identified BMP6 variant. Molecular characterization by immunofluorescence microscopy and Western blotting of transfected cells, bioinformatics, and population analyses was performed. Results In contrast to reports for other Bmp6 pro-peptide variants in this region, our data indicates that this variant does not affect the function of the mature BMP6 protein. Conclusions Our data suggest that assignment of disease causation in clinical cases of iron overload to pro-peptide variants in Bmp6 should thus be treated with caution and requires biological characterization.

Published
2018

16. Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma.

Author

Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, Ribas de Almeida AC, Hajek R, Kim K, Grosicki S, Sia H, Bryant A, Pitombeira de Lacerda M, Aparecida Martinez G, Sureda Balarí AM, Sandhu I, Cerchione C, Ganly P, Dimopoulos M, Fu C, Garg M, Abdallah AO, Oriol A, Gatt ME, Cavo M, Rifkin R, Fujisaki T, Mielnik M, Pirooz N, McKeown A, McNamara S, Zhou X, Nichols M, Lewis E, Rogers R, Baig H, Eccersley L, Roy-Ghanta S, Opalinska J, and Mateos MV

Subjects
Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Antibodies, Monoclonal administration & dosage, Antibodies, Monoclonal adverse effects, Antibodies, Monoclonal, Humanized administration & dosage, Antibodies, Monoclonal, Humanized adverse effects, Kaplan-Meier Estimate, Neoplasm, Residual, Disease Progression, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antineoplastic Combined Chemotherapy Protocols adverse effects, Bortezomib administration & dosage, Bortezomib adverse effects, Dexamethasone administration & dosage, Dexamethasone adverse effects, Multiple Myeloma drug therapy, Multiple Myeloma mortality, Progression-Free Survival
Abstract

Background: Belantamab mafodotin had single-agent activity in patients with relapsed or refractory multiple myeloma, a finding that supports further evaluation of the agent in combination with standard-care therapies., Methods: In this phase 3, open-label, randomized trial, we evaluated belantamab mafodotin, bortezomib, and dexamethasone (BVd), as compared with daratumumab, bortezomib, and dexamethasone (DVd), in patients who had progression of multiple myeloma after at least one line of therapy. The primary end point was progression-free survival. Key secondary end points were overall survival, response duration, and minimal residual disease (MRD)-negative status., Results: In total, 494 patients were randomly assigned to receive BVd (243 patients) or DVd (251 patients). At a median follow-up of 28.2 months (range, 0.1 to 40.0), median progression-free survival was 36.6 months (95% confidence interval [CI], 28.4 to not reached) in the BVd group and 13.4 months (95% CI, 11.1 to 17.5) in the DVd group (hazard ratio for disease progression or death, 0.41; 95% CI, 0.31 to 0.53; P<0.001). Overall survival at 18 months was 84% in the BVd group and 73% in the DVd group. An analysis of the restricted mean response duration favored BVd over DVd (P<0.001). A complete response or better plus MRD-negative status occurred in 25% of the patients in the BVd group and 10% of those in the DVd group. Grade 3 or higher adverse events occurred in 95% of the patients in the BVd group and 78% of those in the DVd group. Ocular events were more common in the BVd group than in the DVd group (79% vs. 29%); such events were managed with dose modifications, and events of worsening visual acuity mostly resolved., Conclusions: As compared with DVd therapy, BVd therapy conferred a significant benefit with respect to progression-free survival among patients who had relapsed or refractory multiple myeloma after at least one line of therapy. Most patients had grade 3 or higher adverse events. (Funded by GSK; DREAMM-7 ClinicalTrials.gov number, NCT04246047; EudraCT number, 2018-003993-29.)., (Copyright © 2024 Massachusetts Medical Society.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results